Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy

Blood. 2022 Mar 3;139(9):1409-1412. doi: 10.1182/blood.2021014989.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • BNT162 Vaccine / administration & dosage*
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Female
  • Humans
  • Immunity, Humoral*
  • Immunization, Secondary*
  • Male
  • Middle Aged
  • Multiple Myeloma* / immunology
  • Multiple Myeloma* / therapy
  • Prospective Studies
  • SARS-CoV-2 / immunology*

Substances

  • BNT162 Vaccine